Markets
MarketMind AI
Baskets
Alerts
F&O
MF
Reports
Screeners
Subscribe
Superstars
Portfolio
Watchlist
Insider Trades
Results
Data Downloader
Events Calendar
What's New
Explore
FAQs
All Features
Widgets
More
Search Stock, IPO, MF
Open in App
IND
USA
IND
IND
×
Close
IND
USA
Stocks
Futures & Options
Mutual Funds
News
Fundamentals
Reports
Corporate Actions
Alerts
Shareholding
Overview
Buy Sell Zone
F&O
Financials
Charts & Report
Charts and Graphs
Stock Report Pdf
News
All
News
Earnings Calls
Corporate Announcements
Research Reports
Reports
Technicals
Technicals
Price History/Seasonality
Delivery
Shareholding
Shareholding
Monthly MF Holdings
Bulk Block Deals
Insider Trading & SAST
Deals
Bulk Block Deals
Insider Trading & SAST
Corporate Actions
All
Dividend
Bonus
Split
Rights
Board Meetings
Alerts
About
Glenmark Pharmaceuticals Ltd.
NSE: GLENMARK
|
BSE: 532296
|
ISIN: INE935A01035
|
Industry: Pharmaceuticals
US FDA Approval
|
Strong Performer, Getting Expensive
2317.9000
-15.00
(
-0.64
%)
NSE
Aug 21, 2026
15:31 PM
29.30% Gain from 52W Low
Volume:
237.4K
Share on Facebook
Tweet
Share on LinkedIn
Share via Whatsapp
Glenmark Pharmaceuticals Ltd.
24 Dec 2024
US FDA Approval
2317.90
-0.64%
GLENMARK PHARMACEUTICALS
Accumulate:
Glenmark Pharmaceuticals Ltd.
by
Geojit BNP Paribas
Target: 1720
Target
Geojit BNP Paribas
Number of FII/FPI investors increased from 436 to 473 in Jun 2026 qtr.
More from Glenmark Pharmaceuticals Ltd.
Recommended
Five Interesting Stocks Today - August 21, 2026
The Baseline |
21 Aug 2026, 04:40PM
Market closes flat as investors turn cautious after Trump’s Iran sanctions announcement
Trendlyne Marketwatch |
21 Aug 2026, 04:01PM
Earnings Call Transcript - Q4FY20 for Glenmark Pharmaceuticals
|
29 Jun 2020